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Abstract
Background: Overweight and metabolic problems now add to the burden of illness in patients with Inflammatory
Bowel Disease. We aimed to determine if a program of aerobic and resistance exercise could safely achieve body
composition changes in patients with Inflammatory Bowel Disease.
Methods: A randomized, cross-over trial of eight weeks combined aerobic and resistance training on body
composition assessed by Dual Energy X-ray Absorptiometry was performed. Patients in clinical remission and
physically inactive with a mean age of 25 ± 6.5 years and Body Mass Index of 28.9 ± 3.8 were recruited from a
dedicated Inflammatory Bowel Disease clinic. Serum cytokines were quantified, and microbiota assessed using
metagenomic sequencing.
Results: Improved physical fitness was demonstrated in the exercise group by increases in median estimated
VO2max (Baseline: 43.41mls/kg/min; post-intervention: 46.01mls/kg/min; p = 0.03). Improvement in body composition
was achieved by the intervention group (n = 13) with a median decrease of 2.1% body fat compared with a
non-exercising group (n = 7) (0.1% increase; p = 0.022). Lean tissue mass increased by a median of 1.59 kg and fat
mass decreased by a median of 1.52 kg in the exercising group. No patients experienced a deterioration in disease
activity scores during the exercise intervention. No clinically significant alterations in the α- and β-diversity of gut
microbiota and associated metabolic pathways were evident.
Conclusions: Moderate-intensity combined aerobic and resistance training is safe in physically unfit patients with
quiescent Inflammatory Bowel Disease and can quickly achieve favourable body compositional changes without
adverse effects.
Trial registration: The study was registered at ClinicalTrials.gov; Trial number: NCT02463916.
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Background
Contrary to the classical phenotype of low body weight
and malnourishment from earlier times, many patients
with Inflammatory Bowel Disease (IBD) are now
overweight or obese [1]. This increases the risk of meta-
bolic disorders such as type two diabetes mellitus and
non-alcoholic fatty liver disease [2]. While some patients
with IBD experience cachexia, particularly those with
advanced Crohn’s disease, modern lifestyles typified by
sedentary living and high-caloric food availability, are
contributing to the increase in obesity and obesity-re-
lated conditions in patients with IBD.
Optimal control of inflammatory activity remains a
primary objective in the treatment of IBD and is an
area in which considerable advances have taken place
in the past decade. However, attention to details such
as the consequences of physical activity through
exercise has received less attention. Known for its
anti-inflammatory and multi-organ metabolic effects
[3, 4], exercise represents first line treatment for
patients with type two diabetes mellitus and
non-alcoholic fatty liver disease [5, 6]. Potential bene-
fits of exercise for patients with IBD extend beyond
metabolic enhancement and include improvements in
quality of life, fatigue levels and bone mineral density.
However, improvement in body composition through
muscle mass accretion remains an underexplored area
that could exert a particularly advantageous effect of
exercise in patients with IBD.
Habitual levels of physical activity in patients with IBD
are significantly lower than in matched controls [7].
When combined with nutrient malabsorption and
corticosteroid treatment, this leads to a higher preva-
lence of sarcopenia in IBD sufferers. Despite improve-
ments in pharmacological treatments, sarcopenia
prevalence in IBD populations remains high (up to 60%
in Crohn’s Disease) [8], irrespective of BMI [9], and
predicts future need for surgical treatment in both
underweight [10] and overweight/obese cohorts [9].
Notwithstanding the likely benefits of exercise in IBD,
there is a paucity of focussed prospective studies [11].
No trials have examined the efficacy or safety of
combined aerobic and resistance (strength) training in
improving body composition and increasing muscle
mass in patients with IBD. Therefore we addressed this
issue in a randomized, controlled cross-over trial to
determine if a combined aerobic and resistance exercise
program could safely and quickly achieve desirable body
compositional changes in patients with IBD.
Methods
Study design and conduct
We performed a single-centre, randomized, partial
cross-over trial recruiting between March and December
2015 (Fig. 1). The trial was registered at https://clinical-
Trials.gov (Trial number: NCT02463916) and conforms
to CONSORT guidelines for randomized controlled
trials. Prior to trial commencement, ethical approval was
granted by the Clinical Research Ethics Committee of
the Cork Teaching Hospitals. All volunteers gave written
informed consent. The clinical notes of age-suitable pa-
tients attending a dedicated Inflammatory Bowel Disease
outpatient clinic at Cork University Hospital, Cork City,
Ireland, were reviewed by the study investigators for ex-
clusion criteria. If no reason for exclusion was apparent,
consecutive patients were invited to participate at the
clinic, by letter or by telephone. Patients were invited to
participate according to a strict, eligibility-based criteria
as outlined below.
Eligible patients were randomized (1:1) by simple
methods (drawing of group numbers from a concealed
container) to one of two groups: Exercise or Control.
Randomization was overseen by two study investigators.
Due to the nature of the intervention, a combined exercise
program, it was not possible to conceal group allocation
to the participants or investigators. Patients randomized
to the exercise group underwent measurement and sam-
pling eight weeks apart (start and end of the intervention
period). During this intervention period, participants in
the exercise group undertook a combined aerobic and re-
sistance exercise program. Patients randomized to the
non-exercising control group initially underwent a
controlled-phase where usual levels of physical inactivity
were maintained for eight weeks. Participants were mea-
sured for primary and secondary outcomes at the start
and end of this period. Following completion of the con-
trol phase, participants then ‘crossed over’ to the interven-
tion arm of the study, where they undertook the same
exercise program for eight weeks (Fig. 1). Volunteers were
again measured at the end of the eight-week intervention
period.
Participants
Male and female patients, aged 18 to 40 years were re-
cruited from a dedicated IBD clinic. All patients, includ-
ing those assigned to the control arm of the study, were
required to have a diagnosis of IBD. Eligible patients
were required to be physically inactive or have low levels
of activity (as defined by the International Physical Ac-
tivity Questionnaire) [12] with no involvement in regular
or organised exercise in the month prior to recruitment.
Furthermore, only patients in disease remission and with
a BMI of 22 to 35 kg/m2 were eligible. Any patients
having experienced a disease flare or having received
treatment with corticosteroids in the two weeks prior to
invitation were excluded. Volunteers who had received
oral antibiotics, bowel preparation, or had suffered an
infectious gastrointestinal illness in the last month were
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also excluded. Patients with a history of total colectomy
were excluded.
Provided eligibility was met, patients were then
required to attend a face-to face screening visit at the
study site (Department of Medicine, Cork University
Hospital, Ireland). Here, patients underwent further
screening and a medical evaluation to ensure safe
participation in the exercise program using an
adapted version of the American College of Sports
Medicine’s safe participation questionnaire [13]. Past
or current medical history of co-morbidities such as
cardiovascular disease or diabetes mellitus excluded
patients from participation.
Intervention and control
Patients randomized to the control phase of the study
were instructed to maintain usual levels of physical
activity (none or low) for the eight-week period. Partici-
pants assigned to the exercise arm of the study, primar-
ily or following cross-over, participated in the same
8-week combined aerobic and resistance training
program. This exercise was moderate in intensity and
progressive, based on the couch to 5 km training
programs. Participants received free gymnasium mem-
bership at the Mardyke Arena at University College
Cork, Ireland, for the duration of the exercise
intervention period and were required to attend three
times per week for eight weeks. Before commencement,
participants were familiarized with the training program
during a 90-min induction session with a study-specific
gym instructor. This included demonstration and prac-
tice with all aerobic and resistance training equipment.
Practical support was provided for participants through-
out by the designated gym staff and study investigators.
Each participant was measured for individual differences
in range of motion on the resistance training machines.
The gym instructor observed the patients using the
machines and provided correction and feedback where
necessary. For resistance machines, one repetition
maximum (1RM) values were calculated using the
Brzycki formula [14].
The outline of the exercise program used is identical
to that described by the authors previously [15].
Volunteers were reminded of the desired intensities on
each of their weekly exercise training program
print-outs. Likewise, compliance with the prescribed
exercise program was reviewed remotely by investigators
using the FitLinxx® activity monitoring system (Shelton,
Connecticut, USA) as outlined previously [15]. Prior to
study commencement, the gym facility’s FitLinxx®
software and hardware was re-calibrated and regularly
maintained throughout.
Fig. 1 Study outline indicating the number of participants at each stage of the study and reasons for exclusion from the trial
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Measurements and efficacy criteria
The primary outcome was change in participant body
composition as determined by Dual Energy X-ray
Absorptiometry (DEXA). A GE Healthcare Lunar iDXA
machine (Madison, Wisconsin, USA) at the Bone Densi-
tometry Unit, Cork University Hospital was used. The
enCORE software (V.13.4, 2010) analysed body compos-
ition using a three-compartment model (fat mass, bone
mass, lean tissue). Total fat mass, truncal fat mass, total
lean tissue mass and percentage body fat were recorded.
Scanning was performed with the volunteers dressed in
light clothing with removal of metal-wear and after they
had voided urine. To reduce potential interference with
true body composition assessment and the effects of di-
urnal variation, patients were measured between 7 a.m.
and 10.30 a.m. and were asked to refrain from alcohol
and moderate to vigorous physical activity for at least
24 h prior to measurement. Quality control analysis was
performed daily on the iDXA machine.
Secondary outcomes included changes in disease
activity scores, quality of life measures, anxiety and
depression indices, serum pro-inflammatory cytokine
levels, and change in the α- and β- diversity of the gut
microbiome. For patients with Crohn’s Disease the
Harvey Bradshaw Index was used to assess disease at the
start and end of the exercise and control periods [16].
For patients with Ulcerative Colitis, the Simple Colitis
Index was used [17]. Patients were instructed to report
any deterioration in gastrointestinal symptoms to the
study team and any symptoms suggestive of a disease
flare meant removal of the patient from the study.
Quality of life was assessed using the Short Form 36
health survey (SF36®V2) [18] at the start and end of the
study periods. Similarly, the Hospital Anxiety and
Depression Scale (HADS) [19], State-Trait Anxiety
Inventory (STAI) [20], and the Beck Depression Inven-
tory II (BDI-II) [21] were used to assess changes in
mood score and psychological well-being.
To assess improvements in physical fitness following
the intervention, all exercising patients underwent
cardiorespiratory fitness testing before and after the
exercise program. To avoid harm from unaccustomed
vigorous exercise, we used a validated, submaximal as-
sessment of peak aerobic capacity to estimate maximal
oxygen uptake (VO2max) [22]. The Rockport one-mile
walk test was performed at the indoor running track of
the Mardyke Arena, Cork. This testing took place in a
standardized temperature environment.
Pro-inflammatory cytokine measurement
All study participants underwent phlebotomy in the
resting state before and after the exercise and control
periods. Approximately 2mls of supernatant sera were
harvested by pipette, frozen and stored at − 80 °C in
polypropylene cryogenic vials. Following collection of all
serum samples, resting pro-inflammatory cytokines were
measured using an electrochemiluminesence-based
solid-phase multiplex assay (MSD; Meso Scale Discovery
platform, Rockville, Maryland, USA). Serum concentra-
tions of interleukins 6, 8, and 10; and Tumour Necrosis
Factor-α (TNF-α) were measured. The lower limit of
detection for the assays was less than 1 pg/ml and
standardized calibration curves were constructed for
each plate. Samples were measured in duplicate and the
mean cytokine concentration (pg/ml) of the duplicates
was used for the subsequent statistical analysis.
DNA extraction and metagenomic sequencing of faecal
microbiome
Patients’ stool samples were collected into a sealed,
secure container and transported to the Teagasc Moore-
park research facility for DNA extraction. DNA was
extracted from fresh faecal material before freezing and
within 6 h of defecation in the vast majority of cases and
never after 12 h. Extraction was performed using a
QIAmp DNA stool minikit (Qiagen, Crawley, West
Sussex, United Kingdom). Faecal sample preparation
prior to DNA extraction and DNA library preparation
was identical to methods previously described by the
authors [15]. An equimolar library pool of all samples
was made prior to sequencing on an Illumina NextSeq
500 (chemistry V.2.0) sequencing platform (Teagasc
sequencing facility). High-throughput sequencing was
performed using the high-output 500/550 reagent kit.
Bioinformatic processing of microbial metagenomic
sequencing
Quality control of metagenomic FASTQ sequences
proceeded with the removal of host (human) reads using
NCBI Best Match Tagger (BMTagger version 1.1.0).
Reads were converted to Binary Alignment Map (BAM)
format and sorted using FastqToSam (version 2.7.1).
Low-quality reads (Phred quality score < 20), adapter
sequences and short reads (Length cutoff: 105 bp) were
trimmed using trimBWAstyle.usingBam.pl script. PCR
duplicates were removed using MarkDuplicates from
Picard tools version 2.7.1. Finally, forward and reverse
reads were merged and converted to FASTA format
using IDBA fq2fa version 1.1.1. The Human Microbiome
Project (HMP) Unified Metabolic Analysis Network
(HUMAnN2 V.0.99) pipeline was used to conduct a
functional profile of high-quality reads [23]. Microbial
metabolic pathway models produced by HUMAnN2
were derived from the MetaCyc database [24] and
formed the analyses performed on microbial metabolic
profiling. Taxonomic profiling was facilitated with the
Kaiju taxonomic assignment software tool (V.1.5.0).
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Sample size and statistical analysis
To detect a 2% reduction in body fat percentage after an
eight-week intervention, with a two-sided significance
level of 5 and 80% power, we calculated a requirement of
seven patients in the control group and 14 in the exercise
group (presuming no loss to follow-up). For statistical
analysis and comparison, patients and their associated
data were grouped according to exercise and control
groups. The relevant data of participants completing the
cross-over phase of the trial were compiled with the exer-
cise group. The Statistical Package for the Social Sciences
V.23 (SPSS Inc., Chicago, Illinois, USA) and the R statis-
tical programming environment (V.3.3.2) were used for
the statistical analysis. As the majority of data was
non-normally distributed, non-parametric analyses were
conducted to compare the groups at baseline. Medians
and interquartile ranges (IQR) are used unless otherwise
stated. Similarly, non-parametric statistical tests were
employed in the analysis of microbiome data. Primary and
secondary analyses were conducted on a per protocol
base. A type I error rate ≤ 0.05 was considered significant
in all cases. Adjustment of significant p-values for multiple
testing was performed using the Bonferroni test [25].
The adonis2 function in the vegan R package (V.2.4–3)
was used to statistically assess dissimilarity matrices
(Bray-Curtis) derived from microbial data [26]. Identifica-
tion of statistically relevant taxonomic features were iden-
tified using the analysis of composition of microbiomes
(ANCOM) test, implemented in the R package (V.1.1–3)
[27]. Measurements of α-diversity and calculations of
relative abundances were also performed with the
vegan package. Relative-abundance data were gener-
ated separately for identified species within each
phylogenetic domain (e.g. Bacteria). Correction of
p-values relating to microbiome analysis was per-
formed using the Benjamini-Hochberg false-discovery
rate (FDR) [28] in the base stats package in R.
Data and software availability
The microbial DNA sequences have been deposited in
the European Nucleotide Database (ENA) database
under ID code PRJEB27623.
Results
Study participants
One hundred and ten patients aged 18 to 40 years were
invited to participate in the trial by letter, phone or in
person at the IBD clinic. Of these, 19 patients were
eligible for enrolment (exclusion reasons specified in
Fig. 1). These patients attended a face-to-face screen-
ing visit and two further patients were excluded based
on their high level of physical activity and their family
history of early coronary artery disease, respectively.
Therefore, 17 patients, with a mean age of 25 ± 6.5
years and BMI of 28.9 kg/m2 ± 3.8, were randomly
allocated to the study arms. Patient characteristics are
described in Table 1 and indicate no significant differ-
ences in clinical variables at baseline between the two
groups, including body composition parameters. Of
the 9 patients assigned to the control phase of the
study, seven patients completed the eight-week con-
trol period and subsequently crossed over to the exer-
cise arm of the study. Of the 15 participants entering
the exercise arm of the study (8 directly randomized
and seven cross-overs), 13 completed the exercise
program. For the two patients who did not complete
the exercise program, one dropped out due to per-
sonal reasons and the other due to time constraints.
Enrolled patients were predominantly overweight or
obese with a median baseline percentage body fat of
35%. Disease activity assessment scores were low at
study entry (Table 2). However, approximately half of
the trial participants had required a treatment course of
corticosteroids in the year leading up to the study. All
patients were receiving some form of disease mainten-
ance therapy including 15% on anti-TNF-α therapy.
Compliance with the prescribed exercise program was
high with exercise group participants attending 87.5% of
gym sessions (averaging 21 out of 24 sessions over 8
weeks). FitLinxx® data recorded that patients in the
exercise group spent a mean 689 ± 113 min in aerobic
exercise over the eight weeks, with an estimated 6813 ±
1952 cal expended during this period. Participants
performed a mean of 4782 ± 812 weight repetitions
during the intervention. Following trial completion,
patients in the exercise group experienced a significant
improvement in cardiorespiratory fitness, as measured
by estimated VO2max (Pre-intervention: 43.41mls/kg/
min; post-intervention: 46.01mls/kg/min; p = 0.03,
Wilcoxon signed-rank test).
Primary outcome
The primary efficacy criterion (body composition change)
was achieved in the exercise group after eight-weeks of
combined aerobic and resistance training (Fig. 2, Table 3).
Participants in the exercise group experienced favourable
changes, with a median (IQR) 2.1% (− 2.15, − 0.45)
decrease in total percentage body fat compared to a
median gain of 0.1% (− 0.4, 1) body fat in the control
participants (p = 0.022). Likewise, patients in the exercise
group experienced a median 1.59 kg (0.68, 2.69) increase
in total lean tissue mass compared to a decrease of 1.38 kg
(− 2.45, 0.26) in the control group (p = 0.003).
Secondary outcomes
Disease activity, quality of life and mood scores
There was no significant deterioration or improve-
ment in disease activity scores in the intervention
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group (Table 3). Participants’ disease activity indices
remained low after 8 weeks of exercise and no patient
was removed from the trial due to a flare of symp-
toms. Two patients, one from each group, required
oral antibiotics during the study for mild, intercur-
rent, non-IBD related infections (1 superficial skin in-
fection and 1 lower respiratory tract infection). These
incidents occurred at the midpoint of the study
(weeks four and five).
There were no statistically significant changes in quality
of life scores (SF36®V2, four physical and four mental
health domains) or mood and anxiety scores (HADS,
STAI, BDI-II) between the control and intervention
groups after eight-weeks (data not shown).
Table 1 Baseline demographic, clinical and anthropometric characteristics of patients in the exercise and non-exercising disease
control groups
Exercise group (n = 13) Control group (n = 7) p-value
Age (years) 33 (31, 36) 31 (31, 36) 0.938
Sex (female) n = 4 (30.8%) n = 1 (14.3%) 0.417a
Height (cm) 172 (165, 179) 173 (167, 183) 0.485
Weight (kg) 84.5 (75.8, 97) 89 (70.5, 102.9) 0.757
BMI (kg/m2) 28.1 (26.2, 32.4) 27.2 (24.5, 33.7) 0.938
Resting heart rate (Beats per minute) 73 (64, 77) 76 (58, 83) 0.817
Systolic Blood Pressure (mmHg) 123 (114, 131) 124 (119, 130) 0.485
Diastolic Blood Pressure (mmHg) 73 (69, 86) 82 (70, 86) 0.311
Body fat (%) 35.2 (30.9, 37.4) 34.2 (32.2, 35.7) 0.817
Fat mass - total (kg) 28.1 (22.8, 35.7) 29.9 (23.8, 34.7) 0.938
Fat mass - trunk (kg) 14.7 (12.9, 21.3) 16.8 (13.1, 22.2) 0.699
Lean tissue mass (kg) 50.2 (44, 61.6) 52.69 (45.8, 63.8) 0.643
Estimated weekly physical activity (kCals) 1017 (283, 1399) 266.9 (0, 1039) 0.097
Median values (inter-quartile ranges) are stated. Mann-Whitney U or Chi-squared test used to compare groups as appropriate. aIndicates Chi-squared test
Table 2 Disease characteristics, baseline disease activity scores and pharmacological treatment of patients in the exercise and
non-exercising disease control groups
Exercise group (n = 13) Control group (n = 7) p-value
Condition (%)
Ulcerative Colitis 8 (61.5%) 5 (71.4%) 0.658a
Crohn’s Disease 5 (38.5%) 2 (28.6%)
Age at diagnosis (years) 25 (25, 31) 26 (22, 31) 0.642
Previous surgery for condition Yes: 1 (7.7%) Yes: 0 0.452a
Baseline Disease activity score
Simple Colitis Index 1.5 (1, 2.75) 1 (0, 4) 0.833
Harvey Bradshaw Index 1 (0, 1.5) 1 (0, 1) 1.00
Disease treatment
Current steroid use None None
Steroid use in the last year (%) Yes: 5 (38.5%)
No: 8 (61.5%)
Yes: 3 (42.9%)
No: 4 (57.1%)
0.848a
Current anti-TNF treatment Yes: 2 (15.4%)
No: 11 (84.6%)
Yes: 1 (14.3%)
No: 6 (85.7%)
0.948a
Currently on immunomodulation Yes: 100% Yes: 100%
Azathioprine N = 1 N = 1
Mesalazine N = 11 N = 6
6-mercaptopurine N = 4 N = 2
Proton pump inhibitors N = 4 N = 4
Proportions, medians (interquartile ranges) are stated as appropriate. Mann-Whitney U and Chi-squared tests performed to compare groups. aIndicates Chi-squared test
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Pro-inflammatory cytokines
Pro-inflammatory cytokines (IL-8, IL-10, IL-6 and
TNF-α) and circulating levels of C-reactive protein
(CRP) were similar at baseline in both groups
indicating low levels of disease activity and there
was no deterioration after the intervention suggest-
ing disease stability with exercise (Additional file 1:
Table S1).
Metagenomic assessment of gut microbiota
There was a modest, but not statistically significant in-
crease in α-diversity (intra-individual) of Archaea species
after the study period (Fig. 3a and b). Mean α-diversity of
bacterial species increased in participants following the
control period (p = 0.015, Fig. 3c), however comparisons
of within-group alterations of α-diversity (percent Δ)
showed no significant differences between exercise and
Fig. 2 Comparison of body composition parameters (a: Total body fat percentage; b: Total lean tissue mass) before and after the combined
aerobic and resistance exercise intervention in the EXERCISE group and in the non-exercising disease CONTROL group. ** Denotes p-value < 0.01
and ***denotes p-value < 0.001 as per Wilcoxon signed-rank test. Error bars denote 95% confidence intervals
Table 3 Change in clinical variables (Δ), body composition parameters and disease activity scores following exercise and control
periods (8 weeks)
Exercise group (n = 13) Control group (n = 7) p-value
Weight (kg) 0 (−1.15, 1.55) −1.6 (−2.1, 0.2) 0.624
BMI (Kg/m2) 0 (−0.395, 0.48) −0.58 (−0.74, −0.54) 0.116
Systolic blood pressure (mmHg) −5 (− 12, − 2) −8 (− 14, − 2) 0.536
Diastolic blood pressure (mmHg) −4 (−8.5, 0.5) −9 (− 10, − 2) 0.311
Resting heart rate (Beats per minute) −7 (− 12, − 2) −1 (−9, 6) 0.211
Total body fat percentage (%) −2.1 (− 2.15, − 0.45) 0.1 (− 0.4, 1) 0.022a
Fat mass - total (kg) − 1.52 (− 2.32, − 0.04) − 0.04 (− 0.93, − 0.04) 0.487
Fat mass - trunk (kg) −0.82 (− 1.4, − 0.002) −0.13 (− 0.8, 0.78) 0.688
Lean tissue mass(kg) 1.59 (0.68, 2.69) −1.38 (− 2.45, 0.26) 0.003a
Change in disease activity score
Simple Colitis Index −1 (− 1, 0) 0 (− 1.5–2) 0.435
Harvey Bradshaw Index 0 (− 1, 0.5) 0 (0, 0) 1.00
Mann-Whitney U tests were used to compare changes in variables between groups. Median values for the change in these variables (interquartile ranges) are
stated. Significant p-values adjusted for multiple comparisons (Bonferroni). aindicates statistical significance
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control groups (Fig. 3e and f ). Similarly, no major shifts
in taxonomic β-diversity (inter-individual) were detected
for bacterial species (Additional file 2: Figure S1A & B),
archaeal species (Additional file 2: Figure S1C & D), or
viral species across both groups (data not presented).
Metabolic pathways generated from metagenomic
data were compared and illustrated subtle, non-signifi-
cant differences within the groups (i.e., week 0 vs. week
8) and across groups. No major, statistically significant
changes were elucidated when α-diversity (Shannon
index) and taxonomic β-diversity of generic and
species-specific pathway models were assessed
(Additional file 3: Figure S2A to Additional file 4:
Figure S3D inclusive).
Discussion
Main findings and relevance
The results show that favourable alterations in body
composition can be achieved over a relatively short
period of time with combined aerobic and resistance
exercise in patients with IBD. This was feasible in seden-
tary patients and without any deterioration in disease
activity or levels of pro-inflammatory cytokines. It is
possible that exercise had additional anti-inflammatory
Fig. 3 α-diversity of taxonomic profiling. (a-d) Shannon α-diversity H-index of Bacteria and Archaea species at week 0 (pre) and week 8 (post).
(a and b) Subtle median increases of Archaea α-diversity for patients in both treatment. (c and d) Bacterial α-diversity was significantly raised in
the control group (p-value = 0.015), while a moderate median decrease was shown in the exercise group. (e) Percent change (Δ) of α-diversity for
Archaea species shows a slight increase in the control group compared to the exercise group (non-significant). (f) Both exercise and control
groups show an increase in α-diversity for Bacteria species. P-values were calculated from the Wilcoxon signed-rank test
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properties that were not assessed in this study. This is
highly likely given the emerging evidence for exercise-in-
duced suppression of inflammation [4, 29]. The
importance of the finding lies in the metabolic benefits
of improving long-term body composition given the in-
creasing risk of obesity and metabolic complications in
patients with IBD [30, 31]. This study should reassure
patients and clinicians that exercise is safe and desirable
and can quickly lead to objectively verifiable improve-
ments in lean tissue mass. Reversing or preventing
sarcopenia in patients with IBD, irrespective of BMI, is
an important goal [9, 10].
This prospective trial also provided us with the oppor-
tunity to explore the influence of exercise on the gut
microbiome of patients with IBD. Recently, research is
converging on the ability of physical activity omultiple
facets of the hepatobiliary-gut axis including the gut
microbiota and bile acid metabolism [32]. Reassuringly,
and contrary to some evidence that exercise has the po-
tential to aggravate gut symptomatology [33], combined
aerobic and resistance exercise of moderate-intensity did
not have detrimental effects on the composition or di-
versity of the gut microbiome. The results demonstrate
similar findings to our previous study in healthy but
physically inactive volunteers, where only modest
changes in the composition and functional capacity of
the gut microbiome occurred following a short-term
period of fitness improvement through an identical
moderate exercise program [15]. It is important to
distinguish the effects of short term exercise from the
physiological changes that occur with sustained fitness
or prolonged high-intensity exercise. This remains to be
assessed in patients with IBD [6]. Indeed, high-intensity
exercise may lead to superior metabolic benefits and
might induce favourable changes in the bacterial micro-
biome in patients with IBD, similar to what has been
observed in professional athletes [34, 35].
Comparison with other studies
The majority of exercise-intervention studies in patients
with IBD have focused on low-impact, aerobic activities
such as walking and almost all studies have been uncon-
trolled [7]. One randomized controlled trial of moderate
intensity outdoor running (three times per week for
10 weeks) demonstrated improved quality of life
measures in patients with mild to moderately active
Crohn’s and Colitis. No adverse events or worsening
of symptoms were reported over a 10-week period
[36], supporting efforts to recommend physical activ-
ity for patients with IBD [11].
Despite established evidence for resistance training in
cancer-related sarcopenia [37], only one, non-randomized
study has examined strength training in IBD reporting
good compliance and improvement in muscle strength
with the prescribed exercise program (thrice-weekly, 12
resistance exercises at 60–70% of one repetition max-
imum) [38]. There was good compliance with the exercise
programme in the present study which is the first ran-
domized controlled trial to examine the role of resistance
training in patients with IBD.
Strengths and limitations
The strengths of this study are several-fold. The cohort
of patients examined in this trial represents a group who
can harness meaningful benefit from lifestyle interven-
tions to improve their metabolic health. At recruitment,
patients in this study were unfit, predominantly over-
weight or obese, with high body fat percentages, placing
them at risk of future metabolic disorders. Following
intervention, this cohort successfully demonstrated
improvements in body composition in a short period of
time. Despite their disease inactivity at study entry, a
large proportion of study participants (almost half ) had
required corticosteroids for disease flare in the previous
12months, and all patients were on disease-controlling
medication. This indicates that patients at risk of disease
flare in the near-future can also benefit from body
composition improvement with exercise and engage in
combined exercise programs without undue concern for
their symptoms. The cross-over design of this study also
represents a strength of this study, reducing the impact
that additional contributory variables (e.g. age, gender,
previous exercise history) may have on the primary out-
come response to exercise intervention by homogenizing
these factors in the exercising and non-exercising
control groups. This is a recognized advantage of this
type of trial design [39].
The study was limited to patients in remission. Other
limitations relate to the relatively short-term follow up
and sample size of the group which may have been
underpowered to detect meaningful changes in second-
ary outcomes. Future studies should be extended to
those patients with co-existing IBD and metabolic disor-
ders including non-alcoholic fatty liver disease and type
two diabetes, who may benefit the most from exercise.
Furthermore, although analysis of the gut microbiome
was not the primary endpoint of interest, inclusion of
samples from two patients receiving broad-spectrum an-
tibiotics mid-way through the study, may be an unavoid-
able confounder. Nevertheless, gut microbial analysis
remained consistent across both exercising and control
groups.
Conclusions
The simple but important ‘take-home’ message for
patients and their doctors is that short-term combined
aerobic and resistance training will achieve favourable
objective changes in body composition in patients with
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IBD and that this is not only safe, but also represents
an inexpensive strategy for the prevention and treat-
ment of IBD-related sarcopenia and obesity-related
metabolic disorders. Policy- and guideline-makers
should consider the addition of regular aerobic and
resistance training to current treatment algorithms for
patients with IBD. Patients should be reassured that
physical activity does not aggravate IBD activity,
particularly in exercise that is gradual and controlled.
Moreover, this study addresses some of the unknowns
relating to exercise in patients with IBD that have
been highlighted previously by others [7, 11]. How-
ever, caution is required before advising patients with
active disease; this requires more study and was not
addressed in the current investigation.
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